Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16052055 | 0.98 | ALDH1A1 (0.58) | ALDH1A1AKR1C3LMNAHPGDCA2 | |
| SCHEMBL20827449 | 0.86 | LMNA (0.48) | ALDH1A1AKR1C3LMNAHPGDL3MBTL1 | |
| SCHEMBL7354123 | 0.80 | LMNA (0.47) | ALDH1A1AKR1C3LMNAHPGDL3MBTL1 | |
| SCHEMBL4797315 | 0.79 | HPGD (0.50) | ALDH1A1LMNAHPGDL3MBTL1MAPT | |
| SCHEMBL28026037 | 0.79 | NOTUM (0.46) | ALDH1A1AKR1C3LMNAL3MBTL1MAPT | |
| SCHEMBL18855830 | 0.79 | ALDH1A1 (0.64) | ALDH1A1AKR1C3LMNAHPGDCA2 | |
| SCHEMBL587681 | 0.78 | LMNA (0.53) | ALDH1A1AKR1C3LMNAL3MBTL1MAPT | |
| SCHEMBL2946268 | 0.77 | HPGD (0.78) | ALDH1A1LMNAHPGDHSD11B1 | |
| SCHEMBL2946264 | 0.77 | HPGD (0.78) | ALDH1A1LMNAHPGDHSD11B1 | |
| SCHEMBL413020 | 0.77 | ALDH1A1 (0.87) | ALDH1A1AKR1C3LMNAHPGDCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | ALDH1A1 2870/4885AKR1C3 2653/4885LMNA 215/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | ALDH1A1 2870/4885AKR1C3 2653/4885LMNA 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.